← All financial models

Johnson & Johnson (JNJ) Financial Model

📊 Download Model

Three-statement Excel model · 18 quarters and 4 fiscal years of history · 10 quarters and 5 fiscal years of projections

current ✓ C13 recon ✓ C14 trace ✓ C15 terminals

About the JNJ model

This three-statement Excel model covers Johnson & Johnson (JNJ): its income statement, balance sheet and cash flow statement. It holds 18 quarters and 4 fiscal years of history and 10 quarters and 5 fiscal years of projections.

Projected revenue is built from KPI drivers: Ten filed franchises grown off the same quarter a year earlier; segment totals sum them, and fiscal 2026's 53rd week sits in the 4Q rates, across 2 segments.

Beyond the income statement, the workbook has these sections: KPI Drivers, Balance Sheet and Cash Flow Statement.

Model thesis: Four years, not five: continuing-ops quarters stop at 1Q22, so the window starts where the Kenvue restatement does rather than opening a 16% basis seam

On October 19, 2026, the model passed checks C13 (every subtotal reconciles to the reported figure at $0), C14 (every projected revenue cell traces to a KPI driver row) and C15 (each driver ends in a rate, a count or a historical anchor, never a typed-in projected dollar level). It was last updated September 22, 2026.

History
18 quarters and 4 fiscal years
Projections
10 quarters and 5 fiscal years
KPI
Ten filed franchises grown off the same quarter a year earlier; segment totals sum them, and fiscal 2026's 53rd week sits in the 4Q rates
Segments
2
Units
Dollars in millions, except per share
Verified
Updated
File
Excel workbook (.xlsx), 165 KB
Access
Free account required: 3 different models a month at no charge, then $9 a month.

Income statement preview

Columns FY2023–FY2025 are actual results and FY26E–FY28E are our estimates. Figures were recalculated in Excel on September 28, 2026. Dollars in millions, except per share.

Income statement preview for JNJ. Dollars in millions, except per share. Actual fiscal years followed by our estimates.
Income Statement
ActualEstimate
FY2023FY2024FY2025FY26EFY27EFY28E
Immunology$18,052.0$17,828.0$15,728.0$15,467.4$16,476.8$17,630.2
Infectious Diseases4,418.03,396.03,241.03,214.33,117.83,024.3
Neuroscience7,140.07,115.07,837.09,158.710,093.710,901.1
Oncology17,661.020,781.025,380.029,646.933,266.936,926.2
Pulmonary Hypertension3,815.04,282.04,437.04,629.24,680.44,680.4
Cardiovascular / Metabolism / Other3,671.03,562.03,778.03,517.63,376.93,241.8
Franchise Rounding (Innovative Medicine)2.00.00.00.00.00.0
Innovative Medicine$54,759.0$56,964.0$60,401.0$65,634.1$71,012.5$76,404.1
Cardiovascular6,350.07,707.08,928.09,485.810,136.710,947.7
Orthopaedics8,942.09,158.09,258.09,750.210,101.510,455.0
Surgery10,037.09,845.010,137.010,558.510,886.411,267.4
Vision5,072.05,146.05,468.05,805.46,087.06,391.3
Franchise Rounding (MedTech)(1.0)1.01.00.00.00.0
MedTech$30,400.0$31,857.0$33,792.0$35,599.9$37,211.5$39,061.4
Total Revenue$85,159.0$88,821.0$94,193.0$101,234.1$108,224.1$115,465.5
Less: Cost of Products Sold($26,553.0)($27,471.0)($30,256.0)($32,451.0)($34,314.7)($36,263.9)
Gross Profit$58,606.0$61,350.0$63,937.0$68,783.1$73,909.4$79,201.6
Less: Selling, Marketing and Administrative Expenses($21,512.0)($22,869.0)($23,676.0)($25,965.2)($27,562.9)($29,176.4)
Less: Research and Development Expense(15,085.0)(17,232.0)(14,665.0)(15,489.5)(16,525.5)(17,516.0)
Less: In-Process Research and Development Impairments(313.0)(211.0)(81.0)(87.9)(108.2)(115.5)
Less: Restructuring(489.0)(234.0)(228.0)(169.7)(216.4)(230.9)
Total Operating Expenses($37,399.0)($40,546.0)($38,650.0)($41,712.4)($44,413.1)($47,038.8)
Operating Income$21,207.0$20,804.0$25,287.0$27,070.7$29,496.3$32,162.8
Interest Income$1,261.0$1,332.0$1,056.0$888.8$919.9$981.5
Less: Interest Expense, Net of Portion Capitalized(772.0)(755.0)(971.0)(1,123.5)(1,190.5)(1,270.1)
Other Income / (Expense), Net(6,634.0)(4,694.0)7,209.0(1,247.3)(1,298.7)(1,385.6)
Earnings Before Provision for Taxes on Income$15,062.0$16,687.0$32,581.0$25,588.7$27,927.0$30,488.6
Less: Provision for Taxes on Income($1,736.0)($2,621.0)($5,777.0)($4,217.0)($4,887.2)($5,335.5)
Net Earnings from Continuing Operations$13,326.0$14,066.0$26,804.0$21,371.7$23,039.8$25,153.1
Net Earnings from Discontinued Operations, Net of Tax21,827.00.00.00.00.00.0
Net Income$35,153.0$14,066.0$26,804.0$21,371.7$23,039.8$25,153.1
Ratios & Assumptions
Gross Margin68.8%69.1%67.9%67.9%68.3%68.6%
Incremental Gross Margin62.1%74.9%48.2%68.8%73.3%73.1%
Operating Margin24.9%23.4%26.8%26.7%27.3%27.9%
Continuing Operations Net Margin15.6%15.8%28.5%21.1%21.3%21.8%
Net Margin41.3%15.8%28.5%21.1%21.3%21.8%

The full workbook adds 18 historical and 10 projected quarters, plus KPI Drivers · Balance Sheet · Cash Flow Statement — every subtotal a live formula, every projection traced to a driver.

Download the full JNJ model (xlsx)3 free models a month with an account, then $9 a month

Johnson & Johnson research

Aardvark Labs Capital Research has published 6 reports on Johnson & Johnson (JNJ). The latest is the Q3 2026 Earnings Recap, published October 19, 2026, rated Hold.

Pharma Carries the Quarter and Talc Finally Has a Price, but MedTech Slows for a Third Straight Quarter: Maintaining Hold as Fair Value Rolls to $230–260

All JNJ research →

Methodology

Every projected revenue cell traces to a KPI/driver row (C14). Terminal driver cells are rates, counts, or historical anchors — never typed-in projected dollar levels (C15). Every subtotal-vs-reported reconciliation row ties to $0 (C13). Each model is written per-ticker against its actual schema — no cloning, no level-input shortcuts.